Intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma is a cancer arising from the cells lining the small bile ducts within the liver. It is the second commonest primary liver cancer after hepatocellular carcinoma, and it behaves differently — it often occurs in a liver that is otherwise healthy, it does not have a characteristic imaging signature, and surgery remains the only treatment offering cure.
How it forms
The bile ducts are lined by cholangiocytes. Chronic inflammation of this lining — from any cause — drives repeated injury and repair, and over time the accumulated genetic damage produces cancer. The tumour then grows as a mass within the liver substance, which is what distinguishes the intrahepatic form from cancers of the larger ducts at the liver hilum or lower down.
Recognised risk factors, all of which share the theme of chronic biliary inflammation or injury:
- Primary sclerosing cholangitis — chronic inflammation and scarring of the bile ducts.
- Chronic liver disease and cirrhosis, from viral hepatitis or other causes.
- Bile duct stones within the liver (hepatolithiasis).
- Congenital biliary abnormalities, including choledochal cysts and Caroli disease.
- Liver fluke infection — a major cause in parts of Asia, uncommon here.
- Certain chemical exposures.
In a substantial proportion of patients no risk factor is identified at all. This is important to say plainly, because patients often search for a cause they could have avoided and there frequently isn't one.
Symptoms
Because the tumour grows within the liver substance rather than obstructing a major duct, jaundice is often absent early on — which is part of why it presents late. Symptoms, when they appear, are non-specific:
- dull upper abdominal pain
- unintentional weight loss
- loss of appetite, fatigue
- night sweats
- jaundice, if the tumour involves larger ducts
A significant number are found incidentally on imaging performed for another reason.
How the diagnosis is made
Contrast-enhanced CT and MRI with MRCP define the tumour, its relationship to the vessels and bile ducts, and the presence of satellite lesions or lymph node involvement. The typical appearance is a mass with rim enhancement and progressive delayed uptake — distinct from the wash-out pattern of HCC, and this distinction matters because the two are managed differently.
CA 19-9 is often raised but is not specific; it can rise in biliary obstruction of any cause and is normal in some patients with cancer.
Biopsy is usually required for diagnosis, unlike HCC, because the imaging appearance is not itself diagnostic. An important caveat: adenocarcinoma on biopsy looks similar whether it arose in the bile ducts or spread to the liver from the pancreas, stomach, colon, breast or lung. Establishing that this is a primary cholangiocarcinoma rather than a metastasis requires staging imaging — usually CT of chest, abdomen and pelvis, endoscopy where indicated, and immunohistochemistry — and that distinction changes treatment entirely.
PET-CT is used in selected cases to look for disease outside the liver.
Treatment
Surgical resection
Complete removal with clear margins is the only treatment that offers cure. This usually means a major liver resection, because the tumour is often large by the time it is found and adequate margins are needed. Assessment of resectability considers:
- whether the tumour can be removed completely with a clear margin
- whether sufficient functioning liver will remain — the future liver remnant
- involvement of the portal vein or hepatic artery
- the presence of multiple tumours within the liver
- lymph node involvement beyond the regional nodes, or spread outside the liver
Regional lymph node dissection is performed as part of the operation, because nodal status is among the strongest predictors of outcome and is needed to guide treatment afterwards.
Where the future liver remnant would be inadequate, portal vein embolisation is used beforehand to make the remaining liver grow, converting some patients from unresectable to resectable. This is one of the reasons a second opinion is worthwhile when a tumour has been declared inoperable on volume grounds.
Chemotherapy
Adjuvant chemotherapy after resection is standard practice and improves outcomes. For unresectable or metastatic disease, systemic chemotherapy is the mainstay, and the addition of immunotherapy to chemotherapy has improved results in recent years. Molecular profiling of the tumour is now routine in advanced disease, because a proportion carry targetable alterations — FGFR2 fusions and IDH1 mutations among them — for which specific drugs exist.
Locoregional therapies
Ablation, transarterial therapies and radiotherapy techniques have a role in selected patients whose disease is confined to the liver but who are not candidates for resection.
Recovery
Major liver resection is significant surgery. Hospital stay is typically five to ten days, and full recovery takes six to twelve weeks. The liver regenerates substantially within weeks in a patient whose underlying liver is healthy. Adjuvant chemotherapy usually begins once recovery is established.
Follow-up
Regular clinical review, imaging and CA 19-9 measurement, most intensively in the first two to three years when recurrence is most likely.
When to seek a specialist opinion
Promptly, and from a unit that performs major liver resection regularly. Two situations particularly justify a second opinion: when a tumour has been declared unresectable, since techniques to increase the liver remnant may alter that judgement; and when a liver adenocarcinoma has been diagnosed without a thorough search for a primary elsewhere, since treating a metastasis as a primary, or the reverse, leads to the wrong operation.
Common questions
What is cholangiocarcinoma?
A cancer arising from the cells lining the bile ducts. When it develops in the ducts within the liver it is called intrahepatic, and it presents as a mass in the liver rather than as jaundice, which distinguishes it from tumours arising in the ducts nearer the intestine.
Why did I get it?
In most people no cause is identified. Recognised risk factors are long-standing inflammation of the bile ducts — from primary sclerosing cholangitis, bile duct stones, congenital abnormalities of the ducts, or, in parts of Asia, liver fluke infection — along with cirrhosis and chronic hepatitis. Chronic irritation of the duct lining over many years is the common thread.
Why was a biopsy taken when liver cancers are often diagnosed on scans alone?
Because unlike hepatocellular carcinoma, this tumour has no diagnostic pattern on scanning and looks very similar to a secondary deposit from a cancer elsewhere. Establishing the diagnosis with tissue, and excluding a primary tumour in the bowel, breast or pancreas, is necessary before treatment is planned.
Can it be cured?
Complete surgical removal offers the only realistic chance of cure, and it is possible in a proportion of patients. Whether it can be done depends on the size and position of the tumour, whether more than one area of the liver is involved, whether major vessels are affected, and how much healthy liver would remain.
Why does the operation involve removing so much liver?
Because this tumour spreads along the bile ducts and into the surrounding liver tissue beyond what is visible, so an adequate margin of normal liver is required. The lymph glands around the liver are also removed, as involvement there is common and affects the treatment plan. The liver regenerates substantially over the following months.
What happens if surgery is not possible?
Chemotherapy, now often combined with immunotherapy, has improved outcomes meaningfully in recent years. Treatments delivered directly into the artery supplying the tumour, and precisely targeted radiotherapy, can control disease confined to the liver. Molecular testing of the tumour is important, as a proportion carry specific genetic changes for which targeted tablets are available.
What is molecular testing and why does it matter?
The tumour tissue is examined for particular genetic alterations — changes in genes such as FGFR2 and IDH1, and mismatch repair deficiency. A meaningful proportion of these tumours carry one, and where they do, specific targeted drugs or immunotherapy can be used that would otherwise not be considered. It is worth asking whether it has been done.
Will it come back?
Recurrence after surgery is unfortunately common, which is why chemotherapy is usually given afterwards and why follow-up scans continue for years. Recurrence confined to the liver can sometimes be treated again, so it is monitored rather than simply awaited.
Related conditions
Other conditions of the liver covered on this site:
- Liver cysts (simple hepatic cysts)
- Hydatid (echinococcal) cyst of the liver
- Liver haemangioma
- Focal nodular hyperplasia and hepatocellular adenoma
- Liver abscess
- Hepatocellular carcinoma (HCC)
- Liver metastases
This page provides general information and does not replace an individual medical consultation. Assessment and treatment are decided for each patient after review of their history, examination and imaging, and in the setting of a multidisciplinary team.